Kwok-Kin Wong
Auto-generated profile, based on publicly available information

Kwok-Kin Wong

Division of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Cell
Verified
Journal Article
Closed access
SSSreenath V. Sharma
Sreenath V. Sharma
DLDiana Y. Lee
Diana Y. Lee
BLBihua Li
Bihua Li
MQMargaret P. Quinlan
Margaret P. Quinlan
FTFumiyuki Takahashi
Fumiyuki Takahashi
JSJeff Settleman
Jeff Settleman

12 February 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CYCai-Hong Yun
Cai-Hong Yun
KMKristen E. Mengwasser
Kristen E. Mengwasser
ATAngela V. Toms
Angela V. Toms
MWMichele S. Woo
Michele S. Woo
HGHeidi Greulich
Heidi Greulich
MEMichael J. Eck
Michael J. Eck
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M. Threonine 790 is the “gatekeeper” residue, an important determinant of inhibitor specificity in the ATP binding pocket. The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors. Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib. Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude. The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance. Crystallographic analysis of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation. We conclude that the T790M mutation is a “generic” resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.

24 July 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
ZCZhao Chen
Zhao Chen
CFChristine M. Fillmore
Christine M. Fillmore
PHPeter S. Hammerman
Peter S. Hammerman
CKCarla F. Kim
Carla F. Kim
KWKwok-Kin Wong
Kwok-Kin Wong

1 July 2018 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
FSFerdinandos Skoulidis
Ferdinandos Skoulidis
MGMichael E. Goldberg
Michael E. Goldberg
DGDanielle M. Greenawalt
Danielle M. Greenawalt
MHMatthew D. Hellmann
Matthew D. Hellmann
MAMark M. Awad
Mark M. Awad
JHJohn V. Heymach
John V. Heymach
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781

17 February 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
SKShohei Koyama
Shohei Koyama
EAEsra Akbay
Esra Akbay
YLYvonne Y. Li
Yvonne Y. Li
GHGrit S. Herter-Sprie
Grit S. Herter-Sprie
KBKevin A. Buczkowski
Kevin A. Buczkowski
PHPeter S. Hammerman
Peter S. Hammerman
Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidate mechanisms of adaptive resistance, we analyse the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma. In tumours progressing following response to anti-PD-1 therapy, we observe upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3), in PD-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade. Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure. These data suggest that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.

17 January 2014 in Science
Verified
Journal Article
Closed access
PDF file
GLGang Lu
Gang Lu
RMRichard E. Middleton
Richard E. Middleton
HSHuahang Sun
Huahang Sun
MNMarkVic Naniong
MarkVic Naniong
COChristopher J. Ott
Christopher J. Ott
WKWilliam G. Kaelin
William G. Kaelin
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.